111 related articles for article (PubMed ID: 37766483)
1. Ligustrazine-Derived Chalcones-Modified Platinum(IV) Complexes Intervene in Cisplatin Resistance in Pancreatic Cancer through Ferroptosis and Apoptosis.
Wang M; Cao G; Zhou J; Cai J; Ma X; Liu Z; Huang X; Wang H
J Med Chem; 2023 Oct; 66(19):13587-13606. PubMed ID: 37766483
[TBL] [Abstract][Full Text] [Related]
2. Novel Platinum(IV) complexes intervene oxaliplatin resistance in colon cancer via inducing ferroptosis and apoptosis.
Liu Z; Cai J; Jiang G; Wang M; Wu C; Su K; Hu W; Huang Y; Yu C; Huang X; Cao G; Wang H
Eur J Med Chem; 2024 Jan; 263():115968. PubMed ID: 37995563
[TBL] [Abstract][Full Text] [Related]
3. Novel Indole-Chalcone Derivative-Ligated Platinum(IV) Prodrugs Attenuate Cisplatin Resistance in Lung Cancer through ROS/ER Stress and Mitochondrial Dysfunction.
Liu Z; Wang M; Huang R; Hu T; Jing Y; Huang X; Hu W; Cao G; Wang H
J Med Chem; 2023 Apr; 66(7):4868-4887. PubMed ID: 36946996
[TBL] [Abstract][Full Text] [Related]
4. Novel 4-Amino-Quinazoline moieties ligated Platinum(IV) prodrugs overcome cisplatin resistance in EGFR
Li R; Zhao W; Jin C; Xiong H
Bioorg Chem; 2023 Jun; 135():106499. PubMed ID: 37058978
[TBL] [Abstract][Full Text] [Related]
5. Dual-target platinum(IV) complexes reverse cisplatin resistance in triple negative breast via inhibiting poly(ADP-ribose) polymerase (PARP-1) and enhancing DNA damage.
Li R; Zhao W; Jin C; Xiong H
Bioorg Chem; 2023 Apr; 133():106354. PubMed ID: 36720184
[TBL] [Abstract][Full Text] [Related]
6. Targeting RAS-RAF pathway significantly improves antitumor activity of Rigosertib-derived platinum(IV) complexes and overcomes cisplatin resistance.
Liu Z; Wang M; Wang H; Fang L; Gou S
Eur J Med Chem; 2020 May; 194():112269. PubMed ID: 32248002
[TBL] [Abstract][Full Text] [Related]
7. Platinum(IV) complexes conjugated with chalcone analogs as dual targeting anticancer agents: In vitro and in vivo studies.
Huang X; Liu Z; Wang M; Yin X; Wang Y; Dai L; Wang H
Bioorg Chem; 2020 Dec; 105():104430. PubMed ID: 33171407
[TBL] [Abstract][Full Text] [Related]
8. Platinum(IV) Prodrugs with Cancer Stem Cell Inhibitory Effects on Lung Cancer for Overcoming Drug Resistance.
Wang X; Liu Z; Wang Y; Gou S
J Med Chem; 2022 Jun; 65(11):7933-7945. PubMed ID: 35635560
[TBL] [Abstract][Full Text] [Related]
9. JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin.
Fokkema E; Groen HJ; Helder MN; de Vries EG; Meijer C
Biochem Pharmacol; 2002 Jun; 63(11):1989-96. PubMed ID: 12093475
[TBL] [Abstract][Full Text] [Related]
10. Anti-cancer effects of newly developed chemotherapeutic agent, glycoconjugated palladium (II) complex, against cisplatin-resistant gastric cancer cells.
Tanaka M; Kataoka H; Yano S; Ohi H; Kawamoto K; Shibahara T; Mizoshita T; Mori Y; Tanida S; Kamiya T; Joh T
BMC Cancer; 2013 May; 13():237. PubMed ID: 23672493
[TBL] [Abstract][Full Text] [Related]
11. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds.
Meijer C; Mulder NH; Timmer-Bosscha H; Sluiter WJ; Meersma GJ; de Vries EG
Cancer Res; 1992 Dec; 52(24):6885-9. PubMed ID: 1458477
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxicity of antitumor platinum complexes with L-buthionine-(R,S)-sulfoximine and/or etanidazole in human carcinoma cell lines sensitive and resistant to cisplatin.
Brooks SE; Korbut TT; Dupuis NP; Holden SA; Teicher BA
Cancer Chemother Pharmacol; 1995; 36(5):431-8. PubMed ID: 7634385
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of ferroptosis in a rat model of premature ovarian insufficiency induced by cisplatin.
Du R; Cheng X; Ji J; Lu Y; Xie Y; Wang W; Xu Y; Zhang Y
Sci Rep; 2023 Mar; 13(1):4463. PubMed ID: 36932163
[TBL] [Abstract][Full Text] [Related]
14. Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study.
Ratzon E; Najajreh Y; Salem R; Khamaisie H; Ruthardt M; Mahajna J
BMC Cancer; 2016 Feb; 16():140. PubMed ID: 26906901
[TBL] [Abstract][Full Text] [Related]
15. Par-4 downregulation confers cisplatin resistance in pancreatic cancer cells via PI3K/Akt pathway-dependent EMT.
Tan J; You Y; Xu T; Yu P; Wu D; Deng H; Zhang Y; Bie P
Toxicol Lett; 2014 Jan; 224(1):7-15. PubMed ID: 24144893
[TBL] [Abstract][Full Text] [Related]
16. Reduction-sensitive platinum (IV)-prodrug nano-sensitizer with an ultra-high drug loading for efficient chemo-radiotherapy of Pt-resistant cervical cancer in vivo.
Luo K; Guo W; Yu Y; Xu S; Zhou M; Xiang K; Niu K; Zhu X; Zhu G; An Z; Yu Q; Gan Z
J Control Release; 2020 Oct; 326():25-37. PubMed ID: 32531414
[TBL] [Abstract][Full Text] [Related]
17. Osthole promotes the suppressive effects of cisplatin on NRF2 expression to prevent drug-resistant cervical cancer progression.
Su J; Zhang F; Li X; Liu Z
Biochem Biophys Res Commun; 2019 Jun; 514(2):510-517. PubMed ID: 31056260
[TBL] [Abstract][Full Text] [Related]
18. Resistance of human cervical carcinoma cells to tumor necrosis factor correlates with their increased sensitivity to cisplatin: evidence of a role for DNA repair and epidermal growth factor receptor.
Nishikawa K; Rosenblum MG; Newman RA; Pandita TK; Hittelman WN; Donato NJ
Cancer Res; 1992 Sep; 52(17):4758-65. PubMed ID: 1380890
[TBL] [Abstract][Full Text] [Related]
19. Elevated pressure, a novel cancer therapeutic tool for sensitizing cisplatin-mediated apoptosis in A549.
Oh S; Kim Y; Kim J; Kwon D; Lee E
Biochem Biophys Res Commun; 2010 Aug; 399(1):91-7. PubMed ID: 20643104
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxicity of cis-[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)]-platinum (II) suspended in Lipiodol in a newly established cisplatin-resistant rat hepatoma cell line.
Kishimoto S; Miyazawa K; Terakawa Y; Ashikari H; Ohtani A; Fukushima S; Takeuchi Y
Jpn J Cancer Res; 2000 Dec; 91(12):1326-32. PubMed ID: 11123433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
